Your post brings sound reasoning and excellent figures for the burgeoning Chinese markets. Those very significant policy changes that now allow two children per family have to be music to our ears.

As you point out, "nothing like Children's RapiMed exists in China". Scrips has exactly the right kind of product for that market, and has been taking all the right steps in good time.